Suitability of 11C-ORM-13070 as a PET Tracer
NCT00735774 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2009-11-25
Summary
The purpose of the study is to evaluate the suitability of 11C-ORM-13070 as a positron emission tomography tracer.
Conditions
- Healthy
Interventions
- DRUG
-
11C-ORM-13070
Single dose of i.v. solution
Sponsors & Collaborators
-
Orion Corporation, Orion Pharma
lead INDUSTRY
Principal Investigators
-
Juha Rinne, MD, PhD · Turku PET Centre
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-08-31
- Primary Completion
- 2009-05-31
- Completion
- 2009-05-31
Countries
- Finland
Study Locations
More Related Trials
-
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
NCT03100136 ·Status: COMPLETED ·Phase: PHASE1
-
F-Tryptophan PET/CT in Human Cancers
NCT05556473 ·Status: RECRUITING ·Phase: PHASE1
-
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
NCT01613703 ·Status: COMPLETED ·Phase: PHASE1
-
A PET Study in Healthy Volunteers
NCT01424449 ·Status: COMPLETED ·Phase: PHASE1
-
Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
NCT03519659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Integrated PET/MR Imaging With Amino Acid Radiotracers in the Evaluation of Brain Neoplasms: Assessing Diagnostic Accuracy and Therapeutic Response
NCT07211360 ·Status: NOT_YET_RECRUITING
-
Tryptophan Metabolism in Human Brain Tumors
NCT02367469 ·Status: COMPLETED
-
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
NCT04715750 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
NCT02978586 ·Status: COMPLETED
-
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
NCT01089998 ·Status: COMPLETED ·Phase: PHASE1
-
PD-L1 PET Imaging in Melanoma Patients
NCT03520634 ·Status: COMPLETED ·Phase: NA
-
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
NCT06411678 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516
NCT00892944 ·Status: COMPLETED ·Phase: PHASE1
-
Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer
NCT00647790 ·Status: COMPLETED
-
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
NCT05228106 ·Status: RECRUITING
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
NCT04263792 ·Status: RECRUITING ·Phase: PHASE1
-
Exploratory Study Using a New Head-only PET Scanner
NCT04511546 ·Status: COMPLETED ·Phase: NA
-
Imaging With [11C]Martinostat in Breast Cancer
NCT03721211 ·Status: WITHDRAWN ·Phase: PHASE1
-
68Ga-Citrate PET of Healthy Volunteers
NCT01951300 ·Status: COMPLETED ·Phase: NA
-
18F-LY3950321-01 Biodistribution and Safety Study
NCT05775601 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Validation of [18F]FES for Imaging of Brain Estrogen Receptors
NCT01842217 ·Status: TERMINATED ·Phase: NA
-
A Phase 1, Open-Label, PET Study of T2310 & BPN14770
NCT04044781 ·Status: WITHDRAWN ·Phase: PHASE1
-
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)
NCT01308905 ·Status: UNKNOWN ·Phase: NA
-
Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction
NCT05537675 ·Status: COMPLETED
-
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT03846167 ·Status: ACTIVE_NOT_RECRUITING